Last reviewed · How we verify
Isoniazid 900 milligrams
Isoniazid 900 milligrams is a Small molecule drug developed by Federal University of Mato Grosso. It is currently FDA-approved. Also known as: Antibiotic Treatment.
Isoniazid 900 milligrams is a small molecule inhibitor of the enzyme Enoyl-[acyl-carrier-protein] reductase [NADH]. It is classified as an inhibitor and is used to target this enzyme, which is involved in the synthesis of mycolic acid in Mycobacterium tuberculosis.
At a glance
| Generic name | Isoniazid 900 milligrams |
|---|---|
| Also known as | Antibiotic Treatment |
| Sponsor | Federal University of Mato Grosso |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isoniazid 900 milligrams CI brief — competitive landscape report
- Isoniazid 900 milligrams updates RSS · CI watch RSS
- Federal University of Mato Grosso portfolio CI
Frequently asked questions about Isoniazid 900 milligrams
What is Isoniazid 900 milligrams?
Who makes Isoniazid 900 milligrams?
Is Isoniazid 900 milligrams also known as anything else?
What development phase is Isoniazid 900 milligrams in?
Related
- Manufacturer: Federal University of Mato Grosso — full pipeline
- Also known as: Antibiotic Treatment
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing